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Abstract: 
 
Trypanosoma brucei, the causative agent of human African trypanosomiasis, also known as 
African sleeping sickness, expresses a protein known as TbLpn which plays a critical role in 
arginine methylation and phospholipid synthesis within T. brucei. In order to determine the 
effect and potential medical benefits of downregulated TbLpn expression in T. brucei, RNA 
interference was used by transfecting T. brucei with plasmid DNA through electroporation. After 
conducting this experimental protocol, T. brucei was unable to be grown successfully in media 
following transfection and the effect of downregulated TbLpn in T. brucei requires further 
investigation in order to determine its potential for developing new drug targets and treatment 
methods for human African trypanosomiasis. Experimental protocol changes and repetition and 
verification of the validity of current protocols could lead the way for successful growth of T. 
brucei with downregulated TbLpn.  
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 5 
Introduction 
 
 Human African trypanosomiasis, also known as African sleeping sickness, is a disease 
caused by the parasite Trypanosoma brucei, a unicellular, flagellated, protozoan (Figure 1). 
Humans become infected with the disease upon being bit by a tsetse fly that is carrying the 
parasite. The disease is present mainly in regions of rural Africa and, due to the limitations of 
resources present in this region, it is very difficult to treat. There are two stages to the disease 
after infection by T. brucei. The first stage of the disease, the hemolymphatic stage, is the easiest 
treat as it is only present throughout the blood and lymphatic system. The second stage of the 
disease, the meningoencephalitic stage, occurs after the disease crosses the blood-brain barrier 
and invades the central nervous system, cerebrospinal fluid, and the brain (Checchi & Barrett, 
2008). Once the disease reaches this stage, the mortality rate is near 100% and drugs can only be 
administered to aid in the treatment of symptoms but are ineffective at killing the parasite and 
treating the disease (Checchi & Barrett, 2008). Very few drugs currently exist for the treatment 
of these symptoms and the drugs that do exist are toxic themselves and patients can often 
contract serious medical complications or die from the medications (Wenzler et al., 2009). Two 
subspecies of T. brucei are responsible for causing several variations of the disease, known as 
East African sleeping sickness and West African sleeping sickness, named after the region in 
which they are most prevalent (CDC, 2012). East African sleeping sickness is caused by T. 
brucei rhodesiense and progresses very quickly, causing death within several months if not 
treated. West African sleeping sickness progresses much slower, over the course of several years, 
and is caused by T. brucei gambiense (Figure 2) (CDC, 2012). 
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Figure 1: Trypanosoma brucei in blood smear stained with Giemsa. T. brucei is a unicellular 
parasite that causes Human African Trypanosomiasis which affects many individuals in sub-
Saharan Africa. T. brucei ranges in length from 15-35 µm. (Centers for Disease Control and 
Prevention). 
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Figure 2: Geographical distribution of East and West African strains of T. brucei. T. brucei 
has two forms. T.b. gambiense is the chronic form and is found in Western and Central Africa 
and T.b. rhodesiense is the acute form found in Southern Africa. These regions, which most of 
the HAT cases are reported within, is referred to as the “Fly belt. (Centers for Disease Control 
and Prevention). 
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 Upon being bit by an infected tsetse fly, a tender sore and swelling occurs around the site 
of the bite. The symptoms of the first stage of human African trypanosomiasis resemble those of 
the flu and include fever, headache, muscle and joint aches, and swollen lymph nodes. Once the 
disease has progressed to the central nervous system, more serious symptoms begin to develop. 
These include an inverted sleep cycle with daytime sleepiness, personality changes, confusion, 
delusions and hallucinations, partial paralysis, and hormone imbalances (CDC, 2012). These 
symptoms become progressively worse as the parasite grows and reproduces until eventual and 
inevitable death occurs.  
 
 During the first stage of the disease, one of the drugs used for treatment is pentamidine, a 
medication that has been around since the 1940s. This drug possesses a wide variety of 
antiparasitic properties and is also used in the treatment of leishmaniasis and Pneumocystis 
infections (Wenzler et al., 2009). This drug is fairly toxic, and its side effects include burning 
pains, chest pains, difficulty breathing, difficulty swallowing, skin rashes, and wheezing (Mayo 
Clinic, 2017). For the late stage of the disease, there are only several drugs that are able to treat 
any of the symptoms associated with this stage. One drug, melarsoprol, is effective at curing the 
disease at a rate of 70%. However, about 5% of patients receiving this drug treatment die from 
encephalopathy, or brain damage that is induced by the drug (Checchi & Barrett, 2008). Another 
drug used for late stage treatment of the disease is eflornithine, which was developed in the 
1990s. It is generally believed that this drug is slightly safer than melarsoprol which is why it is 
more commonly used for late stage disease treatment and distributed to areas in rural Africa by 
the World Health Organization (Checchi & Barrett, 2008). However, one of the issues that has 
been arising with this drug and its continued use in treated human African trypanosomiasis is 
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that several strains of T. brucei are becoming resistant to the drug which renders them ineffective 
(Checchi & Barrett, 2008).  
 
Various organizations are taking action to try and stop the spread of African 
trypanosomiasis, including the World Health Organization. The WHO reports that in 2009 there 
was less than 10,000 cases of the disease in Africa and that in 2015 there was only 2,804 cases 
reported. These cases were mainly present in the Democratic Republic of Congo, at around 70% 
of all confirmed cases of the disease (WHO, 2018). The efforts of the WHO include sending 
skilled medical staff and drugs to regions of Africa where the disease is present in order to try to 
combat it. However, due to the limited medical and financial resources of the regions in which 
the disease is prevalent, the current methods of treatment are not always beneficial to the 
populations in these areas, as more medical complications can arise from treatment. This is why 
a push from the scientific community for research in this field is essential. American 
organizations are also supporting the research of human African trypanosomiasis and T. brucei in 
order to try to help eradicate the disease as well. The National Science Foundation, the National 
Institutes of Health, and the Centers for Disease Control and Prevention are all supporting 
research into the subject in order to try to have a potential cure for the disease or new drug target 
by the World Health Organization’s proposed date of 2020.  
 
 One of the reasons that this disease is so complicated and difficult to treat is because of 
the variant surface glycoproteins (VSG) on the surface of the parasite. Variant surface 
glycoproteins are “developmentally regulated genes that mediate immune evasion (Horn, 2014).” 
The VSG coat is about 15 nanometers thick and is essential for the virulence of the parasite. 
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There are an extremely large number of VSG genes in T. brucei (more than 1,500) however, only 
one can be expressed at a time (Horn, 2014). The main reason that T. brucei is able to evade 
immune responses within their host is because once the immune system develops a response that 
coordinates with the current VSG that is being expressed by the parasite, T. brucei switches from 
one VSG to a different VSG which renders all of the immune cells formed to combat the 
infection useless (Figure 3). This is why a vaccine is unable to be developed to irradiate African 
trypanosomiasis since all VSGs cannot be targeted through one vaccine and would be impossible 
to develop over a thousand vaccines to target every VSG that is expressed by T. brucei.  
 
 Another protein that has been studied and could possibly play a role in T. brucei survival, 
growth, and reproduction is one that is called TbLpn, which stands for T. brucei lipin homologue 
(Figure 4). In many organisms, lipin proteins carry out dephosphorylation of phosphatidic acid 
(PA), generating diacylglycerol (DAG), which is then used to synthesize phosphatidylcholine 
(PC) and phosphatidylethanolamine (PE) (Pelletier et al., 2013). PC and PE are the major 
phospholipids present in trypanosomes and are essential for both life cycle forms of T. brucei to 
grow (Pelletier et al., 2013). It has been shown that TbLpn has phosphatidate phosphatase 
activity, which suggests that TbLpn may play a role in phospholipid synthesis (Pelletier et al., 
2013). TbLpn is a homologue of the lipin proteins found in other organisms. Lipin proteins are 
present in organisms across a wide evolutionary spectrum; these include protozoa, yeast, fish, 
and mammals (Pelletier et al., 2013). Members of the lipin protein family serve many necessary 
cellular functions, but their main functions involve biosynthesis of phospholipids and 
triacylglycerols, acting as a transcriptional cofactor in regulating lipid metabolism genes. 
Additionally, lipin homologues have been shown to play an important role in  
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Figure 3: Antigenic Variation in T. brucei. VSGs can switch from one to another or express a 
clone-specific singular VSG. One switch occurs every 100,000 cells per generation. This 
mechanism of switching is called antigenic variation and allows the parasite to evade the human 
immune system and drug treatments.    
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Figure 4. Schematic representation of TbLpn amino acid sequence aligned with members 
of the lipin family. TbLpn [T. brucei (Tb), accession number AAX78871], Lipin-1 [Human 
(Hs), AAH30537], Lipin-2 [Human (Hs), AAI52449], Lipin-3 [Human (Hs), CAI42978], Lipin-
1 [Mouse (Mm), NP_766538], Lipin-2 [Mouse (Mm), AAH39698], Lipin-3 [Mouse (Mm), 
EDL06298], Lipin-M [Drosophila melanogaster (Dm), NP_001188884], Lipin-1 [Danio rerio 
(Dr), AAX19945], Smp2 [Saccharomyces cerevisiae (Sc), BAA00880] [62] 
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nuclear membrane biogenesis in yeast (Pelletier et al., 2013). TbLpn was shown to have two 
conserved domains that play a role in “adipocyte development and phospholipid biosynthesis in 
mammalian and yeast cells (Pelletier et al., 2013). Additionally, Pelletier et al. found that TbLpn 
was present in the cytosol and the nucleus of T. brucei, along with greatly modified versions of 
TbLpn due to “post-transcriptional modifications.” The study by Pelletier et al. further concluded 
that, as a result of their findings, TbLpn could be responsible for phospholipid synthesis in T. 
brucei and that TbLpn is the “only lipin or phosphatidic acid phosphatase to exhibit post-
transcriptional modifications that include methylated arginine residues in vivo (Pelletier et al., 
2013).” 
 
Arginine methylation is responsible for various cellular processes including “signal 
transduction, RNA transport and processing, protein localization, and transcription (Pelletier et 
al., 2013).” Protein Arginine Methyltransferases (PRMTs) are enzymes that transfer methyl 
groups from AdoMet to the arginine residues in proteins. There are four different types of 
PRMTs, each classified by the way the terminal arginine is modified (Figure 5). The first step in 
arginine methylation is to transfer a single methyl group from AdoMet to the terminal nitrogen 
group on the arginine, creating monomethylarginine (MMA). This step can be completed by 
types I-III PRMTs, however, type III can only catalyze MMA whereas types I and II can also 
catalyze further reactions. Type I PRMTs transfer another methyl group to the same terminal 
nitrogen creating an asymmetric di-methylarginine (ADMA). Type II PRMTs catalyze the 
transfer of a methyl group to the terminal nitrogen group located next to the original terminal 
nitrogen group creating a symmetric di-methylarginine (SDMA). The type IV PRMTs transfer a 
methyl group to the internal nitrogen of the arginine.  
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Figure 5: The four types of PRMTs. Arginine methylation is a post-translational modification 
that transfers methyl groups to the arginine residue and helps to regulate protein function. There 
are four types PRMTs, enzymes that transfer the methyl groups. The four different types of 
PRMTs are each classified by the way the terminal arginine is modified. Type I-III PRMTs 
transfer a single methyl group to the terminal nitrogen group on the arginine residue creating 
monomethylarginine (MMA). Type III can only catalyze this reaction. 
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In T. brucei there are five PRMT enzymes suggesting that arginine methylation has 
distinct contributions during the life cycle of the parasite. The observation that TbLpn has 
methylated arginine residues suggests that it could affect its enzymatic activity or interactions 
with other proteins.  
 
In order to try to down regulate the expression of the TbLpn protein in T. brucei, RNA 
interference is one technique that can be implemented to accomplish this. RNAi is “the 
mechanism through which gene-specific, double-stranded RNA triggers degradation of 
homologous transcripts (Ullu et al., 2004). RNAi is a natural cellular mechanism that can be 
induced in the laboratory environment for experimental use. RNAi functions by targeting cellular 
mRNA which is then degraded by short-interfering RNA and double-stranded RNA. Double-
stranded RNA is cut into smaller fragments by a dicer enzyme which creates short-interfering 
RNA fragments. These siRNA fragments bind to special proteins and remove one of the double-
stranded RNA (Ullu et al., 2004). These siRNA can be engineered to match virtually any gene 
across a variety of organisms. The remaining strand of RNA then binds to mRNA according to 
standard Watson-Crick base pairing. After this point, the mRNA can either be destroyed or 
marked for further regulation (Ullu et al., 2004). Therefore, RNAi is an ideal way to try and 
affect the expression of TbLpn in T. brucei since it can be performed experimentally, while also 
being a natural cell mechanism, and it can be targeted to highly specific genetic regions for a 
specific purpose instead of having a widespread affect across the cell’s genetic material.  
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Figure 6. Down regulation of gene expression by the RNAi machinery. 
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Materials & Methods 
 
 In order to perform a transfection of T. brucei PF 29-13 cells, a very strict protocol must 
be followed in which several experimental techniques are implemented. Each technique must be 
done correctly, otherwise, the subsequent steps will not be able to be conducted successfully and 
the transfection will be ineffective. These procedures include amplification of the 3’ untranslated 
region (UTR) of TbLpn which is then cloned into the P2T7-177 plasmid in order to be 
transformed into Escherichia coli cells, selecting for the cells that have taken up the plasmid with 
ampicillin and then growing them in large quantities, transfecting T. brucei PF 29-13 cells with 
the plasmid using an electroporation machine, and then selecting for the transfected cells using 
phleomycin. This extremely sensitive set of protocols was performed various times in order to 
try to successfully grow T. brucei with the modified DNA in media and sustain them as they 
grow and reproduce.  
 
Cell culture. First, T. brucei PF 29-13 cells were grown in SM media in order to obtain a 
concentration of around 4.6 X 106 cells/ml. This concentration of T. brucei is required in order to 
perform a successful transfection since around 90% of the cells die following the electroporation 
step. The SM medium that was used to grow T. brucei contained 7.4 g of SM powder, 150 mL of 
water, and 625 μl of MEM-vitamins. The pH of the medium was then adjusted by adding NaOH 
until the pH increased from around 4.5 to 7.5. Following this step, water was added to the 
medium mixture in order to obtain a final volume of 225 ml. The medium was then sterilized 
through a filter with 0.22 uM pore size. Following filtration, 25 mL of heat-inactivated fetal 
bovine serum and 2.5 mL of 100x penicillin/streptomycin mixture was added to the medium, 
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also in a sterile environment, and the medium was then distributed to several tubes after the 
addition of a starter culture of T. brucei PF 29-13. The cells were then placed in a rotating 
incubator at 27ºC and allowed to grow until the desired concentration of cells was reached, while 
changing the medium every several days with fresh SM media in order to ensure that the 
increasing acidity of the medium as the cells grow and reproduce does not kill them. The 
increasing acidity can be detected in the medium by the color change from a deep, dark red to a 
more brown/dark yellow color.  
 
Plasmid preparation. In preparation for the transfection, the 3’ UTR of TbLpn was amplified in 
order for use in later experimental procedures. The 3’ UTR of TbLpn was used to target TbLpn 
because it allows for RNAi-directed degradation of TbLpn mRNA and subsequent 
complementation of these TbLpn-RNAi cells with plasmids encoding mutated versions of TbLpn 
without the mutated mRNAs being targeted by the RNAi machinery. TbLpn 3’UTR was 
amplified by 40 cycles of PCR from procyclic form T. brucei genomic DNA using primers 
TbLpn-3UTR-5’ (5’-CGGGATCCTGGCGTGGGTGTGGTGATT-3’) and TbLpn-3UTR-3’ (5’-
CCCAAGCTTGGGGAGTTGTGAGGAAAAGGTGG-3’), which allowed introduction of 
BamHI and HindIII restriction sites respectively (underlined). The PCR product was then cloned 
into the BamHI and HindIII sites of the P2T7-177 plasmid for later use in the transfection of T. 
brucei. Chemically competent E. coli DH5α cells were transformed using published methods. In 
order to select for E. coli cells that have taken up the P2T7-177 plasmid, LB plates containing 
ampicillin were used, since this particular plasmid contains an ampicillin resistance gene. 
Therefore, only cells that have taken up the plasmid DNA will survive in the presence of 
ampicillin.  
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  Next, the plasmid was purified in order to be used during the transfection of T. brucei. In 
order to do this, one liter of E. coli DH5α cells containing the P2T7-177-3’UTR plasmid grown 
overnight at 37ºC in the presence of 100 µg/ml ampicillin. The next morning, the cells were spun 
at 4,000 RPM for 10 minutes at 4ºC in an accuSpin 3R centrifuge (Fisher Scientific). The 
supernatant was then discarded, and the cell pellet resuspended in 10 ml of GTE buffer (50 mM 
of glucose, 25 mM of Tris [pH 8.0], and 10 mM of EDTA). Following gentle mixing, 11.2 ml of 
lysis solution (0.33 M NaOH, 1% SDS) was added to the mixture and the solution was incubated 
on ice for 5 minutes. Then, 19 ml of neutralization solution (3 M potassium acetate, 2 M acetic 
acid) was added to the mixture, and the solution was once again incubated on ice for 10 minutes. 
The mixture was then centrifuged at 14,000 X g for 15 minutes at 4ºC. The supernatant was 
transferred to a clean tube, and 19 ml of isopropanol was added, and the mixture was once again 
centrifuged at 14,000 X g for 2 minutes. The supernatant was discarded and the pellet remaining 
was allowed to air dry for 20 minutes. The pellet was then resuspended in 12.5 ml of TE buffer 
(10 mM Tris [pH 7.6], 1 mM EDTA), and RNAse A was added at a concentration of 0.1 mg/ml. 
The solution was incubated at 37ºC for 15 minutes, centrifuged again at 14,000 X g for 15 
minutes, the supernatant transferred to a new tube, and the plasmid DNA was precipitated with 
3.3 ml of 10 M ammonium acetate and 16.7 ml of isopropanol. Once again, the mixture was 
centrifuged at 14,000 X g for 20 minutes, the supernatant discarded, and the pellet remaining was 
resuspended in 18.75 ml of 70% ethanol. This solution was finally centrifuged one more time at 
14,000 X g for 5 minutes, the supernatant discarded, and the pellet was allowed to air dry before 
it was resuspended in 250 μl of TE buffer. The resulting 250 μl solution was the purified P2T7-
177-3’UTR plasmid.  
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T. brucei transfection. Once the cells are ready to be transfected using the purified P2T7-
177-3’UTR plasmid, the plasmid was digested with the restriction enzyme NotI, which 
recognizes a specific guanine-cytosine sequence for DNA digestion. This linearizes the plasmid 
DNA in preparation for transfection. In order to perform the digestion, 200 μl of the purified 
plasmid (approximately 200 µg) was mixed with 25 μl of 10x green digestion buffer (Fermentas) 
along with 5 μl of NotI restriction enzyme (Fermentas) and 20 μl of deionized or ultraviolet-light 
sterilized water. Digestion was allowed to proceed for 60 minutes at 37ºC. In order to ensure that 
the digestion was done properly, a 1% agarose gel containing 0.5 µg/ml ethidium bromide was 
prepared and allowed to solidify. Then, 5 μl of 1 kb DNA ladder along with a 10 μl solution 
containing 2 μl of undigested P2T7-177-3’UTR plasmid, 1 μl of 10x green digestion buffer, and 
7 μl of water was added to two of the wells of the solidified agarose gel. In addition, 10 μl of the 
digested plasmid was added to a third well in the gel and the gel was run in TAE buffer (40 mM 
Tris [pH 8.0], 20 mM acetic acid, and 1 mM EDTA) in an electrophoresis device at 125 volts for 
40 min. 
  
After confirmation that the plasmid was successfully digested, 50 μg of the digested 
plasmid was used to transfect 4 X 107 PF T. brucei 29-13 cells. In order to perform the 
transfection, a Neon® transfection system from ThermoFisher Scientific was used along with the 
accompanying Neon® transfection buffers and solutions. First, 100 ml of exponential growth T. 
brucei culture in SM medium was centrifuged at 1,300 X g for 10 minutes at room temperature. 
The supernatant was discarded, and the cell pellet was resuspended in 25 ml of sterile PBS buffer 
without calcium or magnesium. This mixture was then centrifuged again at 1,300 X g for 10 
minutes at room temperature. Following centrifugation, the supernatant was once again 
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discarded, and the cell pellet was resuspended in Resuspension buffer R (ThermoFisher 
Scientific) to give the mixture a cellular concentration of 4 X 108 cells/ml. The Neon® 
electroporation tube was then filled with 3 mL of Electrolyte buffer E2 (ThermoFisher 
Scientific), and the tube was inserted into the electroporation machine. Then, 50 µg of NotI-
linearized plasmid was transferred into a sterile 1.5-ml Eppendorf tube. One hundred μl of the T. 
brucei PF 29-13 cells were also added to the Eppendorf tube and the solution was gently mixed. 
The Neon® pipette was then used to extract a pre-measured volume of the cell/DNA mixture and 
the pipette was inserted into the electroporation tube, being cautious to avoid obtaining air 
bubbles in the pipette tip while performing the extraction. These cells were then electroporated to 
incorporate the plasmid DNA into them by exposing them to 3 electrical pulses of 10 
milliseconds each at 1,325 volts in the Neon® electroporation system. Following this step, the 
pipette was removed, and the mixture was transferred to 10 ml of fresh SM medium which also 
contained the antibiotics G418 at a concentration of 15 μg/ml and Hygromycin B at a 
concentration of 50 μg/ml. The extraction of the cell/DNA mixture and electroporation was 
repeated 10 times, placing each set of electroporated cells into a separate tube. The tubes were 
then incubated at 27ºC overnight in the presence of 5% CO2. The next day, phleomycin was 
added to each tube at a concentration of 2.5 μg/ml. The phleomycin works as a selective 
antibiotic that is active against many cells by disrupting the DNA double-helix. Cells resistant to 
phleomycin have special proteins that are able to bind phleomycin and prevent it from destroying 
the DNA. The T. brucei PF 29-13 cells have a resistance to phleomycin upon successful 
electroporation which is why it is used as a selective antibiotic.  
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 Following the electroporation protocol, the cells are maintained in a 27ºC, 5% CO2 
environment, while taking periodic analyses of the cells to determine their growth. After 
electroporation, it takes several weeks for cells that have not died to recover from the intense 
electrical current. Succeeding this time period, growth was determined by analyzing a sample 
from each tube under a microscope, along with observing color changes in the SM media 
resulting from acid production from T. brucei as they continue to grow and reproduce. In tubes 
that had growth, the SM media was changed with fresh media in order to ensure that the 
increasing acidity of the media did not kill the cells. The cells that should have been in the media 
at this point, in theory, would be T. brucei that had successfully taken up the plasmid DNA 
following electroporation. This protocol was repeated several times in order to try to obtain the 
intended outcome.  
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Results 
 
 Unfortunately, T. brucei cells were unable to be grown in significant quantities following 
electroporation. There are many things that can go awry when trying to maintain the T. brucei 
cells in the post-transfection stage. Assuming that the cells did not die from electroporation, 
several complications occurred throughout the various trials conducted of T. brucei transfection. 
In one trial of transfections, the media was contaminated with yeast, most likely Candida 
albicans, and the trypanosomes were unable to be grown in media successfully. In another trial, 
there was an issue with the carbon dioxide incubator and the 5% CO2 environment was unable to 
be maintained and the cells died before the issue was detected. In other trials, growth was simply 
not detected following transfection, indicating that the cells most likely did not survive 
electroporation. No matter how many times the protocol was repeated, an experimental issue 
arose and T. brucei cells were unable to be grown containing any modified DNA that could 
potentially downregulate the expression of TbLpn.  
 
 The difficulty of growing T. brucei following these experimental protocols was clearly 
indicated by the lack of results and inability to grow T. brucei in media successfully. Upon 
several protocol modifications and repeat of current experimental protocols, the intended results 
may be able to be produced and then its subsequent implications analyzed.  
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Discussion 
 
 In order to try to obtain successful results after transfection, various changes could be 
made to increase the probability of a successful outcome. One thing that needs to be reviewed is 
the sterile environment that the experimental protocol was conducted in. During one trial, the 
media was contaminated with yeast, which indicates that the experimental environment was not 
sterile. In order to try to fix this issue in the future, the ultraviolet light that was used for 
sterilization of the environment could be left on longer in order to ensure that all microorganisms 
are killed prior to the preparation of the SM media. Also, the negative pressure hood that was 
used as an experimental workplace should be checked to ensure it was used properly and that 
there are no mechanical issues with it. Additionally, the antibiotics used throughout the various 
experimental protocols should be checked to ensure their effectiveness and their integrity. Other 
antibiotics and selective antibiotics could also be reviewed to use instead of, or in addition to, the 
antibiotics already used in the experimental protocols. The selective antibiotic used in this 
experiment, phleomycin, functions once a plasmid is incorporated into T. brucei through 
electroporation (Jefferies et al., 1993). The antibiotic resistant genetic information is 
“incorporated into the tubulin locus by homologous recombination and originates at the upstream 
tubulin promoter (Jefferies et al., 1993). This was done prior to our experimentation, as the T. 
brucei PF 29-13 already had this antibiotic resistance incorporated into its genetic material. Use 
of this selective antibiotic helps ensure that the media does not get contaminated and T. brucei 
would be able to grow without any hindrance from other microorganisms. Other selective 
antibiotics might also aid in the selection for T. brucei that has taken up plasmid DNA. These 
antibiotics should also be resistant by T. brucei, however, the resistant information should be 
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targeted to a genetic location other than the tubulin locus in order to determine if they are more 
useful than phleomycin or can be used in combination with phleomycin to allow for better 
growth of T. brucei following the transfection protocol.  
 
 Due to the previous studies conducted on TbLpn and its subsequent role in arginine 
methylation and phospholipid synthesis, it can be assumed that TbLpn plays some type of 
essential role in T. brucei. Being able to affect its production in vivo could have significant 
medical implications and lead to the replacement of drugs used to treat human African 
trypanosomiasis and possible new treatment methods that work on specifically targeting T. 
brucei, either in the blood stream or lymphatic system or cerebrospinal fluid, instead of broad 
spectrum anti-parasitic techniques. More specialized forms of treatment are crucial for dealing 
with T. brucei infection due to some of the unique properties it possess, along with other forms 
of trypanosomes. Since there is currently an extensive amount of research being conducted on T. 
brucei, the World Health Organization is predicting that new drug targets and potential infection 
treatments will be discovered within the next 10 years. This is crucial due to the increasing 
resistance T. brucei has developed to current drugs in use for human African trypanosomiasis 
treatment. The drug, melarsoprol, which is used for late stage disease treatment, is taken up by T. 
brucei by the P2 aminopurine transporter. The gene TbAT1 has been shown to play a central role 
in loss of P2 transporter function, causing subsequent T. brucei resistance to melarsoprol 
(Matovu et al., 2003). Therefore, this gene, along with several others, should be considered when 
determining potential drug targets so that resistance can be avoided in newly developed drugs for 
disease treatment. Thus, that is why TbLpn knockdown using RNAi is a promising area of 
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investigation since it could potentially lead to influence of arginine methylation and phospholipid 
synthesis in T. brucei which could alter the virulence of the parasite.  
 
Finally, the protocol needs to be repeated over again, as many times as required, until it 
can be followed all the way through without any experimental or environmental errors. Growing 
T. brucei following electroporation is a tedious and sensitive process. The process can be 
disrupted by the slightest miscalculation of media ingredient concentrations, temperature 
changes, or environmental gases present. Only repeating this protocol error-free can ensure that 
nothing hinders the growth of T. brucei. Once able to grow T. brucei in significant quantities 
following electroporation, the effects of downregulated TbLpn can be fully studied and its 
implications analyzed. This could lead the way for potential drug targets to combat human 
infection of T. brucei and subsequent contraction of African sleeping sickness.  
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